(Q39510365)

12 September 2017

title

Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists (English)

1 reference

12 September 2017

1 reference

1 reference

Yanping Hu

1

1 reference

12 September 2017

Matthew Gale

2

1 reference

12 September 2017

Jacqueline Shields

3

1 reference

12 September 2017

Carrie Garron

4

1 reference

12 September 2017

Mark Swistak

5

1 reference

12 September 2017

Tri-Hung Nguyen

6

1 reference

12 September 2017

Gary Jacques

7

1 reference

12 September 2017

Robert Fogle

8

1 reference

12 September 2017

William Siders

9

1 reference

12 September 2017

Johanne Kaplan

10

1 reference

12 September 2017

publication date

18 August 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

53

1 reference

12 September 2017

issue

1

1 reference

12 September 2017

page(s)

130-138

1 reference

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

CXCR4 is a prognostic marker in acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

CXCL12 (SDF-1)/CXCR4 pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.601698

10.3109/10428194.2011.601698

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference